Mark Hamblin, MD
Internal Medicine · Kansas City, KSNPI 1588758502
Payments from drug & device makers
Across 565 payments — averaging $9122.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2.1M
- Boehringer Ingelheim$1.6M
- Roche Products Limited$835K
- Cumberland Pharmaceuticals, Inc.$119K
- CSL Behring$102K
- Biogen$84K
- plus $270K from 13 others
Across 2 payments — averaging $925.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
- Biogen$141
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 17 | $2,095,310 |
| Boehringer Ingelheim | 184 | $1,648,692 |
| Roche Products Limited | 54 | $834,753 |
| Cumberland Pharmaceuticals, Inc. | 14 | $118,962 |
| CSL Behring | 45 | $102,140 |
| Biogen | 2 | $84,166 |
| Novartis | 6 | $78,645 |
| Mallinckrodt Hospital Products Inc. | 14 | $74,029 |
| Boehringer Ingelheim International GmbH | 110 | $53,852 |
| Genentech, Inc. | 9 | $44,698 |
| Boehringer Ingelheim France S.a.s. | 55 | $7,626 |
| Genentech USA, Inc. | 3 | $4,372 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 37 | $4,022 |
| United Therapeutics Corporation | 8 | $2,130 |
| Eli Lilly | 1 | $500 |
| ANI Pharmaceuticals, Inc. | 2 | $232 |
| Insmed, Inc. | 2 | $32 |
| Shire North American Group Inc | 1 | $14 |
| AstraZeneca | 1 | $12 |
How this compares
$5,154,189 in reported general payments places this provider in the 95th percentile of 705 internal medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Kansas City
- Leslie SpikesKansas City$4.5M
- Shadi HamdehKansas City$1.1M
- Kyle WorkKansas City$863K
- Lucas PittsKansas City$314K
- Aaron RohrKansas City$136K
- Kyle JanssonKansas City$95K
- Lewis SatterwhiteKansas City$49K
- Martin KankamLeavenworth$63.4M
- Katherine WillinghamTopeka$4.8M
- Raed Al RajabiWestwood$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.